Metall Zug AG Class B · SIX:METN
Metall Zug AG Class B — Merger or Acquisition (November 2023)
18 slides from Metall Zug AG Class B's merger presentation, Nov 28, 2023
Slide 1: Metall Zug AG - Welcome
METALL ZUG AG - WELCOME Investor-Call - November 28, 2023: Joint Venture with Miele/Steelco for Infection Control and Life Science Martin Wipfli, Chairman of the Board of Directors Matthias Rey, CEO Urs Scherrer, CFO Investor-Call - November 28, 2023 1
Slide 2: Welcome Remarks by Martin Wipfli, Chairman of the BoD
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE WELCOME REMARKS BY MARTIN WIPFLI, CHAIRMAN OF THE BOD New strategy communicated in 2019: Transformation of Metall Zug AG into a holding company with substantial investments in attractive industrial companies Focused implementation of th
Slide 3: Background of the Transaction
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE BACKGROUND OF THE TRANSACTION – Metall Zug signed an agreement with Miele for the creation of a Joint Venture (JV) in the area of Infection Control and Life Science to combine Belimed and Steelco – JV to be established in Zug, Switzerla
Slide 4: Structure of the Transaction
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE STRUCTURE OF THE TRANSACTION 67% 33% Joint Venture (CH) Investor-Call - November 28, 2023 4
Slide 5: Supervisory Board of Joint Venture
SUPERVISORY BORD OF JOINT VENTURE – Operational management is intended to be carried out by a joint team with representatives from Belimed, Steelco and Miele – Joint venture will be jointly managed, with Metall Zug providing two of five board members: Investor-Call - November 28, 2023 5
Slide 6: Strategic Goals for Belimed Infection Control & Life Science 2023
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE STRATEGIC GOALS FOR BELIMED INFECTION CONTROL & LIFE SCIENCE 2023 – Growth opportunities and strategic alliances – Achieve sustainable profitability – Organic sales growth in equipment, increase share in recurring revenues with consumab
Slide 7: Background of the Transaction – Growth Factors
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE BACKGROUND OF THE TRANSACTION – GROWTH FACTORS Market Customer environment requirements Global healthcare and life science market has Higher throughput and faster cycle times become one of fastest growing industries worldwide Increasing
Slide 8: Strategic Picture: Sales Approach
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE STRATEGIC PICTURE Success factors Life Market Players and Full solutions offering with large product Time sales approach (2022) portfolio, service and consumables Getinge - illustrative - 724 M€ Steris Handling of complex tenders in pri
Slide 9: Miele and Steelco (as per end of 2022)
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE MIELE AND STEELCO (AS PER END OF 2022) Headquarters Riese Pio X, Italy Zug, Switzerland Production sites Riese Pio X and Cusano, Italy Sulgen, Switzerland Grosuplje, Slovenia Employees ~800 ~1,300 Sales in 2022 EUR 194 million1) CHF 229
Slide 10: Aim of the Transaction
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE AIM OF THE TRANSACTION Belimed and Steelco share comparable values and will complement each other in their markets, products and competences Belimed Steelco – strong regional presence in growth markets, – strong regional presence in Eur
Slide 11: Advantages for All Stakeholders (1/2)
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE ADVANTAGES FOR ALL STAKEHOLDERS (1/2) Transaction represents an excellent strategic option for both companies: – Through bundling of forces, Belimed and Steelco can speed up their development to become the most innovative and customer-o
Slide 12: Advantages for All Stakeholders (2/2)
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE ADVANTAGES FOR ALL STAKEHOLDERS (2/2) For customers: – Benefit from extended and more efficient product portfolio – Customized solutions as well as competent and fast service – Potential for synergies in production, R&D, marketing and s
Slide 13: Timeline
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE TIMELINE Signing Closing expected End of integration 2034: JV is laid-out November, 2023 HY 1, 2024 phase, 2027 for 10 years PMI Execution Review by relevant competition authorities Growth phase Development of Target Picture Metall Zug
Slide 14: Financial Impact on Metall Zug Group
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE FINANCIAL IMPACT ON METALL ZUG GROUP – Consolidation of Belimed Infection Control and Belimed Life Science in the Metall Zug financial statements until closing, which occurs presumably in HY 1 2024. The respective result will be include
Slide 15: Metall Zug AG – Q & A
METALL ZUG AG – Q & A Investor-Call - November 28, 2023: Joint Venture with Miele/Steelco for Infection Control and Life Science Martin Wipfli, Chairman of the Board of Directors Matthias Rey, CEO Urs Scherrer, CFO Investor-Call - November 28, 2023 15
Slide 16: Financial Calendar
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE FINANCIAL CALENDAR March 11, 2024 Publication of Annual Report April 26, 2024 Expected date for ordinary Annual General Meeting of Shareholders 2024 August 8, 2024 Publication of Half Year Results 2024 Investor-Call - November 28, 2023
Slide 17: Contact
JOINT VENTURE WITH MIELE FOR INFECTION CONTROL AND LIFE SCIENCE CONTACT Matthias Rey CEO Urs Scherrer CFO Bettine Killmer Head of Investor Relations & Corporate Communication E-Mail: Investorrelations@metallzug.ch Phone: +41 58 768 60 50 Metall Zug AG Industriestrasse 66 6302 Zug Switzerland Investo
Slide 18: Disclaimer
METALL ZUG GROUP DISCLAIMER Metall Zug AG has made great efforts to include accurate and up-to-date information in this document. However, we make no representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this document and disclaim any